Achillion Pharma (ACHN) Posts Narrower-than-Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Achillion (ACHN) Decline Called Over-Reaction at Deutsche Bank
November 4, 2014 11:23 AM ESTDeutsche Bank maintained a Buy rating on Achillion Pharmaceuticals (NASDAQ: ACHN) with a price target of $17. The stock declined Tuesday after it reported Q3 results. Analyst Alethia Young thinks today's decline on concerns about the timing of 3422 data is an overreaction.
"Based on our call volume, we have gotten questions as to whether this is a delay or not. We have always... More
Achillion Pharma (ACHN): Hard to Read Anything into Absence of 3422 Data, Says Wells Fargo
November 4, 2014 10:17 AM ESTWells Fargo maintained an Outperform rating on Achillion Pharmaceuticals (NASDAQ: ACHN) with a price target of $15-$17. Comments follow Q3 results. Analyst Brian Abrahams noted Achillion did not provide data on its 3422 nuc, but he thinks it's on track to be... More
